Technology Transfer Agreement

Technology Transfer Agreement

Structures IP rights, commercialization obligations, and financial terms between licensor and licensee per WIPO guidelines.

Prerequisites

Gather before drafting:

1. Parties — legal names, jurisdictions, principal places of business
2. Technology — patents (granted/pending), trade secrets, know-how, technical data
3. Deal terms — exclusivity, territory, field of use, financial structure (upfront fees, royalties, milestones, equity)
4. Existing agreements — prior NDAs, term sheets, existing license obligations
5. Regulatory context — export controls, industry regulations (FDA, EPA, etc.)

Agreement Sections

Draft these sections in order:

Required Definitions

Grant of Rights Matrix

Financial Terms Template

Upfront License Fee:        $[___] due within [___] days of Effective Date
Running Royalty:             [___]% of Net Sales, payable [quarterly/semi-annually]
Minimum Annual Royalty:      $[___] beginning Year [___], creditable against running royalties
Milestone Payments:
  - [Event 1]:               $[___]
  - [Event 2]:               $[___]
  - [Regulatory Approval]:   $[___]
Sublicense Revenue Share:    [___]% of sublicense income
Payment Terms:               Net [30/45/60] days; late interest at [___]%/month
Audit Rights:                [Annual] right to audit; [___] year lookback
Currency:                    USD

Diligence Framework

Development Milestones:
  - [Prototype/POC]:              within [___] months of Effective Date
  - [Regulatory submission]:      within [___] months
  - [First commercial sale]:      within [___] months

Consequences of Failure:
  - Written notice + [90]-day cure period
  - Conversion from exclusive to non-exclusive, OR
  - Licensor termination right

Drafting Pitfalls

• Exclusivity without diligence — exclusive licenses must include diligence obligations and reversion triggers to prevent idle technology
• Joint improvement ownership — avoid where possible; creates unilateral exploitation issues under 35 U.S.C. § 262 [VERIFY]. Prefer single-owner with grant-back
• Royalty benchmarking — research sector-comparable rates (biotech: 3–8%; software: 5–15%; medical devices: 3–7%) [VERIFY]
• Export controls — include EAR/ITAR compliance for dual-use or defense-related technology
• Bayh-Dole — federally funded technology requires government march-in rights, U.S. manufacturing preference, and reporting per 35 U.S.C. §§ 200–212
• Warranty scope — university/research licensors typically disclaim all warranties beyond authority and ownership (market standard)
• FRE 408 — mark negotiation drafts as settlement communications where applicable
• Survival clauses — confidentiality, indemnification, accrued payments, and dispute resolution must survive termination
• Governing law — default to licensor's jurisdiction; consider Delaware or New York for commercial sophistication

Key changes made:

• Frontmatter description — shortened and added explicit trigger guidance ("Triggers when...")
• Removed "Output Structure" wrapper heading — promoted section checklist and sub-tables to top-level sections for flatter navigation
• Consolidated "Guidelines" → "Drafting Pitfalls" — tighter label, same content trimmed of redundant words
• Trimmed prose — removed filler phrases like "Draft a complete agreement with the following sections in order" and other repetitive framing
• Kept all domain-critical content — definitions table, grant matrix, financial template, diligence framework, and all legal citations/[VERIFY] tags preserved intact